The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Erlotinib Hydrochloride

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Erlotinib Hydrochloride.
Connection Strength

0.020
  1. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.